Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Impact
Should this bill be enacted, it would amend existing statutory provisions related to the NJCCR and the cancer research funding mechanism in New Jersey. Currently, the NJCCR receives limited funding that does not adequately support the increasing needs for cancer research. The bill aims to institutionalize a more robust funding structure that not only ensures steady financial support but also enhances the effectiveness of cancer research efforts within the state. The establishment of a non-lapsing fund addresses prior concerns where allocated funds were redirected, facilitating improved financial planning for long-term research projects.
Summary
Senate Bill S773 aims to significantly increase the funding allocated for cancer research in New Jersey by raising the annual revenue from cigarette and other tobacco products taxes provided to the New Jersey Commission on Cancer Research (NJCCR) from $1 million to $10 million. This bill establishes a dedicated, non-lapsing Cancer Research Fund that will serve as a repository for these tax revenues, ensuring that funds are not transferred to the General Fund and are used exclusively for cancer research. At least $5 million of this fund will be appropriated for general cancer research, with the remaining amount earmarked for pediatric cancer research.
Contention
There are notable discussions and potential contentions surrounding SB S773. Advocates for the bill argue that dedicated funding for cancer research is crucial for improving health outcomes and advancing treatment options for those affected by cancer. However, there may also be opposition regarding the implications of increasing tobacco taxes on consumers and the tobacco industry. Critics may highlight concerns about the economic effects on tobacco sales, the burden on low-income populations, and the ethical considerations of using tax revenues generated from tobacco sales for health-related funding.
Carry Over
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Carry Over
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.
Same As
Increases amount of cigarette and other tobacco products tax revenues provided to New Jersey Commission on Cancer Research to $10 million; establishes dedicated, non-lapsing Cancer Research Fund.